Clinical data | |
---|---|
Other names | PF-06865571 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H21N5O4 |
Molar mass | 407.430 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ervogastat is an experimental small-molecule drug and selective diacylglycerol O-acyltransferase 2 inhibitor developed by Pfizer for non-alcoholic steatohepatitis. [1] Its development was previously halted by the company but resumed in 2022. [2]
Clinical data | |
---|---|
Other names | PF-06865571 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H21N5O4 |
Molar mass | 407.430 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ervogastat is an experimental small-molecule drug and selective diacylglycerol O-acyltransferase 2 inhibitor developed by Pfizer for non-alcoholic steatohepatitis. [1] Its development was previously halted by the company but resumed in 2022. [2]